← All trials
NCT02981212
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2016
- Primary completion
- Aug 1, 2018
- Completion date
- Oct 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Yonsei UniversityLead sponsor
- Yonsei UniversityOverall official - principal investigator
- Yonsei UniversityReponsible party - principal investigator
- Inje UniversityCollaborator
- Catholic University of KoreaCollaborator
- Kyung Hee UniversityCollaborator
- Chonbuk National UniversityCollaborator
- Chong Kun Dang PharmaceuticalCollaborator
- Kyungpook UniversityCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.